Login
INSMED Inc logo

INSMED Inc

insmed.com

What Do They Do?

Sells ARIKAYCE, an inhaled medicine for adults with MAC lung disease, and BRINSUPRI for people with bronchiectasis.

How Do They Make Money?

Insmed earns revenue by selling ARIKAYCE and BRINSUPRI; sales count when customers receive the products.

revenue
SegmentShareRevenue
ARIKAYCE
Sold outright

72%
BRINSUPRI
Sold outright

28%

Who Are Their Customers?

U.S. buyers include specialty pharmacies and a specialty distributor. ARIKAYCE is sold internationally and in the U.S., while BRINSUPRI sales are in the U.S.

Do Revenues Turn Into Profits?

No. It lost $1.3B in FY2025.

Operating income, FY2025
−206% of revenue
▼ −42% (Loss) vs FY2024 (−$878.3M, −241%)
Net income, FY2025
−211% of revenue
▼ −40% (Loss) vs FY2024 (−$913.8M, −251%)
Free cash flow, FY2025
−160% of revenue
▼ −37% (Loss) vs FY2024 (−$705.8M, −194%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +268%
vs $142.3M in Q3 FY2025
Net income
▲ +73% (Loss)
vs −$370M in Q3 FY2025
ARIKAYCE external R&D expenses share of revenue vs 80.3% in Q3 FY2025
  • Aug 6, 2026 Insmed raises BRINSUPRI revenue guidance It raised full-year guidance to $1.25 billion to $1.40 billion and reiterated ARIKAYCE guidance of $450 million to $470 million.

Growing. Revenue grew 3.2x in 4 years, from $188.5M in FY2021 to $606.4M in FY2025, about 34% a year.

BRINSUPRI becomes a marketed product BRINSUPRI moved from a development candidate for bronchiectasis to a marketed treatment; the latest report says it was approved in the U.S. and Europe and launched in the U.S.

Gene therapy candidates advance The latest report names clinical-stage gene therapy candidates for Duchenne muscular dystrophy and amyotrophic lateral sclerosis, while the older report described gene therapy as an early-stage research modality.

Revenue over time
ARIKAYCE BRINSUPRI
$1B$500M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support